RU2002101651A - Method for improving transportation through an easily adjustable semipermeable barrier - Google Patents
Method for improving transportation through an easily adjustable semipermeable barrierInfo
- Publication number
- RU2002101651A RU2002101651A RU2002101651/14A RU2002101651A RU2002101651A RU 2002101651 A RU2002101651 A RU 2002101651A RU 2002101651/14 A RU2002101651/14 A RU 2002101651/14A RU 2002101651 A RU2002101651 A RU 2002101651A RU 2002101651 A RU2002101651 A RU 2002101651A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- chloro
- composition
- concentration
- penetrants
- Prior art date
Links
- 238000004642 transportation engineering Methods 0.000 title 1
- -1 poly (hydroxyethyl) - Chemical class 0.000 claims 63
- 239000000203 mixture Substances 0.000 claims 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 36
- 239000010410 layer Substances 0.000 claims 25
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 24
- 150000002632 lipids Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 239000002253 acid Substances 0.000 claims 21
- 239000011780 sodium chloride Substances 0.000 claims 21
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 20
- 239000003795 chemical substances by application Substances 0.000 claims 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 20
- 229960001639 penicillamine Drugs 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012528 membrane Substances 0.000 claims 16
- 210000004379 Membranes Anatomy 0.000 claims 15
- 239000011148 porous material Substances 0.000 claims 15
- 239000007788 liquid Substances 0.000 claims 14
- 230000000875 corresponding Effects 0.000 claims 13
- 150000002148 esters Chemical class 0.000 claims 13
- 230000015572 biosynthetic process Effects 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 238000005755 formation reaction Methods 0.000 claims 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 12
- 239000004094 surface-active agent Substances 0.000 claims 12
- 239000000463 material Substances 0.000 claims 11
- 239000004698 Polyethylene (PE) Substances 0.000 claims 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 10
- 229920000573 polyethylene Polymers 0.000 claims 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 10
- 241000196324 Embryophyta Species 0.000 claims 9
- 210000003491 Skin Anatomy 0.000 claims 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 8
- 150000007513 acids Chemical class 0.000 claims 8
- 235000019445 benzyl alcohol Nutrition 0.000 claims 8
- 229960004217 benzyl alcohol Drugs 0.000 claims 8
- 229920001223 polyethylene glycol Polymers 0.000 claims 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 8
- 235000010323 ascorbic acid Nutrition 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drugs Drugs 0.000 claims 7
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 claims 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 6
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims 6
- 210000004400 Mucous Membrane Anatomy 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229940075579 Propyl Gallate Drugs 0.000 claims 6
- BGNXCDMCOKJUMV-UHFFFAOYSA-N TBHQ Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 150000001298 alcohols Chemical class 0.000 claims 6
- 239000003963 antioxidant agent Substances 0.000 claims 6
- 235000006708 antioxidants Nutrition 0.000 claims 6
- 239000003899 bactericide agent Substances 0.000 claims 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 238000001914 filtration Methods 0.000 claims 6
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 150000002989 phenols Chemical class 0.000 claims 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 6
- 239000000473 propyl gallate Substances 0.000 claims 6
- 235000010388 propyl gallate Nutrition 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims 6
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims 6
- 239000011732 tocopherol Substances 0.000 claims 6
- 125000002640 tocopherol group Chemical group 0.000 claims 6
- 235000019149 tocopherols Nutrition 0.000 claims 6
- 229930003799 tocopherols Natural products 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 5
- 239000011668 ascorbic acid Substances 0.000 claims 5
- 229960005070 ascorbic acid Drugs 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 238000002156 mixing Methods 0.000 claims 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims 4
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 4
- ATMNQRRJNBCQJO-UHFFFAOYSA-N 4-hexoxy-2,3,6-trimethylphenol Chemical compound CCCCCCOC1=CC(C)=C(O)C(C)=C1C ATMNQRRJNBCQJO-UHFFFAOYSA-N 0.000 claims 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 4
- 239000005711 Benzoic acid Substances 0.000 claims 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 4
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims 4
- 229960003260 Chlorhexidine Drugs 0.000 claims 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 4
- 229960004926 Chlorobutanol Drugs 0.000 claims 4
- 210000003038 Endothelium Anatomy 0.000 claims 4
- 241000305071 Enterobacterales Species 0.000 claims 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 4
- KSEBMYQBYZTDHS-HWKANZROSA-N Ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims 4
- LNTHITQWFMADLM-UHFFFAOYSA-N Gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 229960003180 Glutathione Drugs 0.000 claims 4
- 108010024636 Glutathione Proteins 0.000 claims 4
- LHGVFZTZFXWLCP-UHFFFAOYSA-N Guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 4
- 241000498779 Myristica Species 0.000 claims 4
- 235000009421 Myristica fragrans Nutrition 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 4
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims 4
- 241001529742 Rosmarinus Species 0.000 claims 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Salvin Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims 4
- 229940075582 Sorbic Acid Drugs 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims 4
- 241001148470 aerobic bacillus Species 0.000 claims 4
- 230000003078 antioxidant Effects 0.000 claims 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 4
- 235000010233 benzoic acid Nutrition 0.000 claims 4
- 150000003842 bromide salts Chemical class 0.000 claims 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 238000001704 evaporation Methods 0.000 claims 4
- 239000000284 extract Substances 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 235000001785 ferulic acid Nutrition 0.000 claims 4
- 229940114124 ferulic acid Drugs 0.000 claims 4
- 238000007710 freezing Methods 0.000 claims 4
- 239000007789 gas Substances 0.000 claims 4
- 235000011187 glycerol Nutrition 0.000 claims 4
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims 4
- 229960004068 hexachlorophene Drugs 0.000 claims 4
- 238000000265 homogenisation Methods 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 4
- 239000001702 nutmeg Substances 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 230000003647 oxidation Effects 0.000 claims 4
- 238000007254 oxidation reaction Methods 0.000 claims 4
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 229940001584 sodium metabisulfite Drugs 0.000 claims 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 4
- 235000010199 sorbic acid Nutrition 0.000 claims 4
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 claims 4
- 239000004334 sorbic acid Substances 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- 239000002562 thickening agent Substances 0.000 claims 4
- 238000000108 ultra-filtration Methods 0.000 claims 4
- 229940049964 Oleate Drugs 0.000 claims 3
- 210000002257 embryonic structures Anatomy 0.000 claims 3
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 3
- 229940070765 laurate Drugs 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 claims 3
- 230000035515 penetration Effects 0.000 claims 3
- 229920001296 polysiloxane Polymers 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 238000010025 steaming Methods 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 2
- FVNKWWBXNSNIAR-BYPYZUCNSA-N (2S)-2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical class OC(=O)[C@@H](N)CC1=CNC(=S)N1 FVNKWWBXNSNIAR-BYPYZUCNSA-N 0.000 claims 2
- VMMUGOUUBVDDPV-UHFFFAOYSA-N 1,2,3,3a-tetrahydroindeno[1,2-g]indole Chemical compound C1=CC2=C3C=CC=CC3=CC2=C2C1CCN2 VMMUGOUUBVDDPV-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- SKDGWNHUETZZCS-UHFFFAOYSA-N 2,3-ditert-butylphenol Chemical compound CC(C)(C)C1=CC=CC(O)=C1C(C)(C)C SKDGWNHUETZZCS-UHFFFAOYSA-N 0.000 claims 2
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-Dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 claims 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 claims 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical group COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 2
- IIYSTUUVIASHBG-YEUHZSMFSA-N 2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid;sodium Chemical compound [Na].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 IIYSTUUVIASHBG-YEUHZSMFSA-N 0.000 claims 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(E,2S,3R)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims 2
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 claims 2
- CRZGAOZTOAGGTQ-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)-[1,3]thiazolo[3,2-b][1,2,4]triazin-7-one Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N3N=CC(=O)N=C3SC=2)=C1 CRZGAOZTOAGGTQ-UHFFFAOYSA-N 0.000 claims 2
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-Hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 claims 2
- YKXAYLPDMSGWEV-UHFFFAOYSA-N 4-hydroxybutyl 2-methylprop-2-enoate Chemical class CC(=C)C(=O)OCCCCO YKXAYLPDMSGWEV-UHFFFAOYSA-N 0.000 claims 2
- GPGNGBOTUUNOLQ-UHFFFAOYSA-N 4-oxo-2-phenyl-2,3-dihydrochromene-3-carbaldehyde Chemical class O1C2=CC=CC=C2C(=O)C(C=O)C1C1=CC=CC=C1 GPGNGBOTUUNOLQ-UHFFFAOYSA-N 0.000 claims 2
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical group O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 claims 2
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 2
- 229940022659 Acetaminophen Drugs 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 2
- 240000002234 Allium sativum Species 0.000 claims 2
- 208000007502 Anemia Diseases 0.000 claims 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 2
- 241000416162 Astragalus gummifer Species 0.000 claims 2
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 claims 2
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 claims 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 2
- 229940105657 CATALASE Drugs 0.000 claims 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N Caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 claims 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 2
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 claims 2
- 240000005497 Cyamopsis tetragonoloba Species 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical class C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 2
- 229940009976 Deoxycholate Drugs 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 229960003887 Dichlorophen Drugs 0.000 claims 2
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophene Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 claims 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N Diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 claims 2
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims 2
- 102000016938 EC 1.11.1.6 Human genes 0.000 claims 2
- 108010053835 EC 1.11.1.6 Proteins 0.000 claims 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N Elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 210000002615 Epidermis Anatomy 0.000 claims 2
- 239000005770 Eugenol Substances 0.000 claims 2
- 229960002217 Eugenol Drugs 0.000 claims 2
- 229960004369 Flufenamic Acid Drugs 0.000 claims 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 2
- 229950002499 Fytic acid Drugs 0.000 claims 2
- 102000006587 Glutathione Peroxidase Human genes 0.000 claims 2
- 108020004973 Glutathione Peroxidase Proteins 0.000 claims 2
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 2
- 229960001867 Guaiacol Drugs 0.000 claims 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- 229960000905 Indomethacin Drugs 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 Inositol Drugs 0.000 claims 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical class OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims 2
- 229940119837 Isopropyl Alcohol Drugs 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 239000002211 L-ascorbic acid Substances 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- 235000013628 Lantana involucrata Nutrition 0.000 claims 2
- SYELZBGXAIXKHU-UHFFFAOYSA-N Lauryldimethylamine oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 2
- 229940105132 Myristate Drugs 0.000 claims 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
- UMWKZHPREXJQGR-UHFFFAOYSA-N N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical group CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 claims 2
- OGUKJRCPWCNIQL-QFHJOOASSA-N N-methyl-N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OGUKJRCPWCNIQL-QFHJOOASSA-N 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 240000007673 Origanum vulgare Species 0.000 claims 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical group N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N P-Chlorocresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims 2
- 229960002895 Phenylbutazone Drugs 0.000 claims 2
- XEBWQGVWTUSTLN-UHFFFAOYSA-M Phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 claims 2
- 229940067605 Phosphatidylethanolamines Drugs 0.000 claims 2
- 229940067626 Phosphatidylinositols Drugs 0.000 claims 2
- 229940067631 Phospholipids Drugs 0.000 claims 2
- 229940068041 Phytic Acid Drugs 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- AAWZDTNXLSGCEK-WYWMIBKRSA-N Quinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-N 0.000 claims 2
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 claims 2
- 235000002912 Salvia officinalis Nutrition 0.000 claims 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N Sinapinic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 claims 2
- 210000002356 Skeleton Anatomy 0.000 claims 2
- 208000006641 Skin Disease Diseases 0.000 claims 2
- BTURAGWYSMTVOW-UHFFFAOYSA-M Sodium laurate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims 2
- 229940082004 Sodium laurate Drugs 0.000 claims 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N Sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide Dismutase Proteins 0.000 claims 2
- 240000005147 Syzygium aromaticum Species 0.000 claims 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 2
- 229920001615 Tragacanth Polymers 0.000 claims 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- 229940116269 Uric Acid Drugs 0.000 claims 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 2
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2R)-2-[(3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000004931 aggregating Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims 2
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 2
- 235000010208 anthocyanin Nutrition 0.000 claims 2
- 239000004410 anthocyanin Substances 0.000 claims 2
- 150000004636 anthocyanins Chemical class 0.000 claims 2
- 229930002877 anthocyanins Natural products 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000111 anti-oxidant Effects 0.000 claims 2
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 claims 2
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000004982 aromatic amines Chemical class 0.000 claims 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims 2
- 229940034794 benzylparaben Drugs 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 239000000560 biocompatible material Substances 0.000 claims 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 2
- 229940067596 butylparaben Drugs 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 235000004654 carnosol Nutrition 0.000 claims 2
- 229920001525 carrageenan Polymers 0.000 claims 2
- 235000010418 carrageenan Nutrition 0.000 claims 2
- 239000003093 cationic surfactant Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 239000000919 ceramic Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 150000001805 chlorine compounds Chemical class 0.000 claims 2
- 229940099352 cholate Drugs 0.000 claims 2
- 235000013985 cinnamic acid Nutrition 0.000 claims 2
- 229930016911 cinnamic acid Natural products 0.000 claims 2
- 235000017803 cinnamon Nutrition 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 2
- 150000001896 cresols Chemical class 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 claims 2
- 229960003964 deoxycholic acid Drugs 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960000616 diflunisal Drugs 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 150000002019 disulfides Chemical class 0.000 claims 2
- 125000004016 elaidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000002255 enzymatic Effects 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 150000002213 flavones Chemical class 0.000 claims 2
- 229930003944 flavones Natural products 0.000 claims 2
- 235000011949 flavones Nutrition 0.000 claims 2
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical class O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 claims 2
- 229930003935 flavonoids Natural products 0.000 claims 2
- 150000002215 flavonoids Chemical class 0.000 claims 2
- 235000017173 flavonoids Nutrition 0.000 claims 2
- 150000002217 flavonols Chemical class 0.000 claims 2
- 229930003933 flavonols Natural products 0.000 claims 2
- 235000011957 flavonols Nutrition 0.000 claims 2
- 235000004515 gallic acid Nutrition 0.000 claims 2
- 235000004611 garlic Nutrition 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 229960005219 gentisic acid Drugs 0.000 claims 2
- 229940050410 gluconate Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000005456 glyceride group Chemical group 0.000 claims 2
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 2
- 230000002209 hydrophobic Effects 0.000 claims 2
- 229960004337 hydroquinone Drugs 0.000 claims 2
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 claims 2
- 235000010359 hydroxycinnamic acids Nutrition 0.000 claims 2
- 229930005346 hydroxycinnamic acids Natural products 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims 2
- 229960004592 isopropanol Drugs 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 235000006677 lemon beebalm Nutrition 0.000 claims 2
- 125000005644 linolenyl group Chemical group 0.000 claims 2
- 125000005645 linoleyl group Chemical group 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229960003464 mefenamic acid Drugs 0.000 claims 2
- 150000002731 mercury compounds Chemical class 0.000 claims 2
- 229940100892 mercury compounds Drugs 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-O methylammonium Chemical class [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000006011 modification reaction Methods 0.000 claims 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-M myristate Chemical compound CCCCCCCCCCCCCC([O-])=O TUNFSRHWOTWDNC-UHFFFAOYSA-M 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- 239000000025 natural resin Substances 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 2
- 235000004383 oregano Nutrition 0.000 claims 2
- 235000018838 origanum vulgare Nutrition 0.000 claims 2
- 230000003204 osmotic Effects 0.000 claims 2
- 229960000649 oxyphenbutazone Drugs 0.000 claims 2
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 239000001814 pectin Substances 0.000 claims 2
- 235000010987 pectin Nutrition 0.000 claims 2
- 229920001277 pectin Polymers 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 150000007965 phenolic acids Chemical class 0.000 claims 2
- 235000009048 phenolic acids Nutrition 0.000 claims 2
- 239000002530 phenolic antioxidant Substances 0.000 claims 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 2
- 125000001095 phosphatidyl group Chemical group 0.000 claims 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 150000008106 phosphatidylserines Chemical class 0.000 claims 2
- 239000000467 phytic acid Chemical class 0.000 claims 2
- 235000002949 phytic acid Nutrition 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229920000058 polyacrylate Polymers 0.000 claims 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims 2
- 229920000515 polycarbonate Polymers 0.000 claims 2
- 239000004417 polycarbonate Substances 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 2
- 229920000193 polymethacrylate Polymers 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 2
- 229960003415 propylparaben Drugs 0.000 claims 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 2
- 238000005096 rolling process Methods 0.000 claims 2
- 235000002020 sage Nutrition 0.000 claims 2
- 229960004889 salicylic acid Drugs 0.000 claims 2
- 239000001296 salvia officinalis l. Substances 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 2
- 229940001607 sodium bisulfite Drugs 0.000 claims 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 2
- 229940104256 sodium taurate Drugs 0.000 claims 2
- WYPBVHPKMJYUEO-NBTZWHCOSA-M sodium;(9Z,12Z)-octadeca-9,12-dienoate Chemical compound [Na+].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O WYPBVHPKMJYUEO-NBTZWHCOSA-M 0.000 claims 2
- 238000000527 sonication Methods 0.000 claims 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 2
- 239000001593 sorbitan monooleate Substances 0.000 claims 2
- 150000003410 sphingosines Chemical class 0.000 claims 2
- 235000013599 spices Nutrition 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 238000003892 spreading Methods 0.000 claims 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000003890 succinate salts Chemical class 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 150000003871 sulfonates Chemical class 0.000 claims 2
- 150000003462 sulfoxides Chemical class 0.000 claims 2
- 235000018553 tannin Nutrition 0.000 claims 2
- 229920001864 tannin Polymers 0.000 claims 2
- 239000001648 tannin Substances 0.000 claims 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-M taurocholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-M 0.000 claims 2
- AWDRATDZQPNJFN-VAYUFCLWSA-M taurodeoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-M 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- 229960004906 thiomersal Drugs 0.000 claims 2
- 235000010487 tragacanth Nutrition 0.000 claims 2
- 150000003852 triazoles Chemical class 0.000 claims 2
- 229960003500 triclosan Drugs 0.000 claims 2
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims 2
- 125000005314 unsaturated fatty acid group Chemical group 0.000 claims 2
- 235000012141 vanillin Nutrition 0.000 claims 2
- 229940117960 vanillin Drugs 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- PJUIMOJAAPLTRJ-GSVOUGTGSA-N (R)-monothioglycerol Chemical compound OC[C@@H](O)CS PJUIMOJAAPLTRJ-GSVOUGTGSA-N 0.000 claims 1
- UIEVCEQLNUHDIF-UHFFFAOYSA-N 1-chloro-2,4-dimethylbenzene Chemical group CC1=CC=C(Cl)C(C)=C1 UIEVCEQLNUHDIF-UHFFFAOYSA-N 0.000 claims 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N 3-Mercaptopropane-1,2-diol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 1
- 229940022663 Acetate Drugs 0.000 claims 1
- 208000005676 Adrenogenital Syndrome Diseases 0.000 claims 1
- 206010003504 Aspiration Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010061590 Blood disease Diseases 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008129 Cerebral palsy Diseases 0.000 claims 1
- 210000003679 Cervix Uteri Anatomy 0.000 claims 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N Chloroxylenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims 1
- 208000010007 Cogan Syndrome Diseases 0.000 claims 1
- 208000008448 Congenital Adrenal Hyperplasia Diseases 0.000 claims 1
- 208000002573 Connective Tissue Disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000005679 Eczema Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 210000004907 Glands Anatomy 0.000 claims 1
- 208000005209 Hematologic Disease Diseases 0.000 claims 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000007313 Kawasaki disease Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N Linoleic acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- KUDPGZONDFORKU-UHFFFAOYSA-N N-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N Nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 210000003800 Pharynx Anatomy 0.000 claims 1
- 229920002367 Polyisobutene Polymers 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 206010036376 Post herpetic neuralgia Diseases 0.000 claims 1
- 229940069328 Povidone Drugs 0.000 claims 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 206010038683 Respiratory disease Diseases 0.000 claims 1
- 206010072736 Rheumatic disease Diseases 0.000 claims 1
- 206010039083 Rhinitis Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 210000002268 Wool Anatomy 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive Effects 0.000 claims 1
- 201000004384 alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 210000000459 calcaneus Anatomy 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000007799 cork Substances 0.000 claims 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 231100001003 eczema Toxicity 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000003475 lamination Methods 0.000 claims 1
- 229940049918 linoleate Drugs 0.000 claims 1
- 201000009673 liver disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 239000011241 protective layer Substances 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001949 retinal vasculitis Diseases 0.000 claims 1
- 230000000552 rheumatic Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000004781 supercooling Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002525 ultrasonication Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 201000011528 vascular disease Diseases 0.000 claims 1
Claims (88)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP99/04659 | 1999-07-05 | ||
PCT/EP1999/004659 WO2001001962A1 (en) | 1999-07-05 | 1999-07-05 | A method for the improvement of transport across adaptable semi-permeable barriers |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2002101651A true RU2002101651A (en) | 2003-10-10 |
RU2260445C2 RU2260445C2 (en) | 2005-09-20 |
Family
ID=8167360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002101651/15A RU2260445C2 (en) | 1999-07-05 | 2000-07-05 | Method for improving transportation through easily adaptable semi-permeable barrier |
Country Status (18)
Country | Link |
---|---|
US (2) | US7459171B2 (en) |
EP (1) | EP1189598A1 (en) |
JP (1) | JP2003503442A (en) |
KR (1) | KR100852901B1 (en) |
CN (1) | CN1359288A (en) |
AU (2) | AU5409699A (en) |
BR (1) | BR0012178A (en) |
CA (1) | CA2375157A1 (en) |
CZ (1) | CZ200238A3 (en) |
EE (1) | EE200200008A (en) |
HK (1) | HK1046356A1 (en) |
HR (1) | HRP20010881A2 (en) |
HU (1) | HUP0201454A3 (en) |
MX (1) | MXPA02000053A (en) |
NO (1) | NO20020032L (en) |
PL (1) | PL352380A1 (en) |
RU (1) | RU2260445C2 (en) |
WO (2) | WO2001001962A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2572959C2 (en) * | 2010-06-29 | 2016-01-20 | Кордис Корпорейшн | Method for medicinal product packing into implantable medical devices (versions) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
MXPA00006196A (en) * | 1998-10-23 | 2003-07-21 | Idea Ag | Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates. |
JP2002533379A (en) | 1998-12-23 | 2002-10-08 | イデア アクチェンゲゼルシャフト | Improved formulation for locally non-invasive use in vivo |
ES2173679T3 (en) | 1999-01-27 | 2002-10-16 | Idea Ag | IMMUNIZATION / TRANSNASAL TRANSPORTATION WITH HIGHLY ADAPTABLE VEHICLES. |
ES2173678T3 (en) | 1999-01-27 | 2002-10-16 | Idea Ag | VACCINATION NOT INVASIVE THROUGH THE SKIN. |
MXPA02000053A (en) * | 1999-07-05 | 2003-07-21 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers. |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
NZ534377A (en) * | 2002-03-13 | 2008-04-30 | Collagenex Pharm Inc | Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion. |
US8435942B2 (en) | 2002-05-31 | 2013-05-07 | Transdermal Biotechnology, Inc. | Methods for formulating stabilized insulin compositions |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
GB2398495B (en) * | 2003-01-23 | 2007-08-22 | Kent G Lau | A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug |
TWI322008B (en) | 2003-01-31 | 2010-03-21 | Kaneka Corp | Fatigue improving agent including reduced coenzyme q10 |
US7354980B1 (en) | 2004-03-12 | 2008-04-08 | Key Medical Technologies, Inc. | High refractive index polymers for ophthalmic applications |
JP2008514606A (en) * | 2004-09-24 | 2008-05-08 | リポ ケミカルズ インコーポレイテッド | Delivery system for topically applied compounds |
CA2584475A1 (en) * | 2004-11-12 | 2006-05-18 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
US7446157B2 (en) | 2004-12-07 | 2008-11-04 | Key Medical Technologies, Inc. | Nanohybrid polymers for ophthalmic applications |
KR20070097092A (en) * | 2005-01-14 | 2007-10-02 | 리포 케미컬즈 인크. | Composition and method for treating hyperpigmented skin |
KR101430767B1 (en) | 2005-07-18 | 2014-08-19 | 유니버시티 오브 메사츄세츠 로웰 | Compositions and methods for making and using nanoemulsions |
DE102005051550A1 (en) * | 2005-10-27 | 2007-05-03 | Fibertex A/S | Superhydrophobic coating of a polymer fleece, in particular a polypropylene fleece |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
PT3295955T (en) | 2005-12-01 | 2021-07-12 | Univ Massachusetts Lowell | Botulinum nanoemulsions |
US9393218B2 (en) | 2005-12-23 | 2016-07-19 | Epinamics Gmbh | Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers |
US20070154403A1 (en) * | 2006-01-05 | 2007-07-05 | Thomas Skold | Oral, Pulmonary and Transmucosal Delivery Composition |
CN107080703A (en) * | 2006-12-01 | 2017-08-22 | 安特里奥公司 | Peptide nanoparticles and its purposes |
WO2008070538A2 (en) * | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
US7713196B2 (en) * | 2007-03-09 | 2010-05-11 | Nellcor Puritan Bennett Llc | Method for evaluating skin hydration and fluid compartmentalization |
EP2162117B1 (en) | 2007-05-31 | 2018-02-21 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
WO2009086137A1 (en) * | 2007-12-21 | 2009-07-09 | Zars Pharma, Inc. | Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs |
US20090184047A1 (en) * | 2008-01-14 | 2009-07-23 | Sankaran Thayumanavan | Functionalized nanopore membranes and related methods of use |
US20090286907A1 (en) * | 2008-01-23 | 2009-11-19 | Beltz Mark W | Fumaric Acid/Diol Polyesters and Their Manufacture and Use |
US8602961B2 (en) * | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
KR101848095B1 (en) * | 2008-06-26 | 2018-04-11 | 안테리오스, 인코퍼레이티드 | Dermal delivery |
US20100009424A1 (en) * | 2008-07-14 | 2010-01-14 | Natasha Forde | Sonoporation systems and methods |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
NZ598906A (en) * | 2009-08-21 | 2014-08-29 | Targeted Delivery Technologies Ltd | Vesicular formulations |
JP2013514347A (en) * | 2009-12-16 | 2013-04-25 | シャスン ファーマシューティカルズ リミテッド | Dexibuprofen transdermal hydrogel composition |
WO2012094033A1 (en) * | 2011-01-05 | 2012-07-12 | Livon Laboratories | Methods of making liposomes, liposome compositions made by the methods, and methods of using the same |
CA2825417A1 (en) * | 2011-01-25 | 2012-08-02 | The Procter And Gamble Company | Liposome and personal care composition comprising thereof |
JP2014508166A (en) | 2011-03-17 | 2014-04-03 | トランスダーマル バイオテクノロジ インコーポレーテッド | Local nitric oxide system and method of use thereof |
EP2688554A2 (en) * | 2011-03-21 | 2014-01-29 | Gregor Cevc | Optimised preparations of highly adaptable aggregates |
US8685106B2 (en) | 2011-11-15 | 2014-04-01 | Abraham Lin | Method of a pharmaceutical delivery system for use within a joint replacement |
US9386792B2 (en) * | 2011-11-29 | 2016-07-12 | Conopco, Inc. | Meal intended for human consumption |
US9656051B2 (en) | 2011-12-01 | 2017-05-23 | Avery Dennison Retail Information Services, Llc | Devices with selectively permeable barriers |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
WO2014070769A1 (en) | 2012-10-29 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
CN103285742B (en) * | 2013-06-26 | 2014-09-03 | 浙江大学 | Preparation method of quaternary ammonium salt type cationic polymer modified chitosan nanofiltration membrane |
WO2015006528A1 (en) * | 2013-07-10 | 2015-01-15 | Jie Zhang | A kit for sustained transdermal drug delivery using liquid or semisolid formulations and method of using the same |
RU2695325C1 (en) * | 2014-02-03 | 2019-07-23 | Апурано Фармасьютикэлс Гмбх | Nanosuspensions of natural materials and method for production thereof |
JP6734781B2 (en) | 2014-03-14 | 2020-08-05 | ゴジョ・インダストリーズ・インコーポレイテッド | Hand sanitizer with improved aesthetics and skin conditioning to encourage adherence to hand hygiene guidelines |
RU2571072C1 (en) * | 2014-11-24 | 2015-12-20 | Гурам Георгиевич Сабаев | Agent for treating and preventing itching dermatosis |
EP3247333B1 (en) | 2015-01-20 | 2021-07-21 | Tetraderm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
AU2016247674A1 (en) * | 2015-04-14 | 2017-10-19 | Atossa Genetics Inc. | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
LT3316857T (en) | 2015-06-30 | 2021-11-25 | Sequessome Technology Holdings Limited | Multiphasic compositions |
WO2017079764A1 (en) * | 2015-11-06 | 2017-05-11 | Bkr Ip Holdco Llc | Method for the attenuation enhancement of absorbent materials used in both passive and active transdermal drug delivery systems |
CN105727773B (en) * | 2016-03-02 | 2018-11-13 | 同济大学 | A kind of anti-bacterial and anti-fouling dyeing polymer seperation film and preparation method thereof |
CN109071750B (en) | 2016-03-08 | 2022-08-02 | 生活实验公司 | Long-lasting cosmetic composition |
CN106176607A (en) * | 2016-07-10 | 2016-12-07 | 中国农业科学院烟草研究所 | A kind of method of Tobacco Chlorogenic Acid nanometer liposome embedding |
MX2019005833A (en) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Transdermal delivery of large agents. |
CN106669439B (en) * | 2016-12-28 | 2019-04-16 | 前沿新材料研究院(深圳)有限公司 | Reverse osmosis membrane of stable against biological contamination and preparation method thereof |
CN107474454B (en) * | 2017-07-13 | 2020-10-16 | 北京华腾新材料股份有限公司 | Preparation method of dimming transparent heat-insulation co-extrusion polyolefin film |
JP2020529229A (en) * | 2017-07-26 | 2020-10-08 | コリウム, インコーポレイテッド | Percutaneous delivery system with microporous membranes with solvent-filled pores |
CN116832020A (en) | 2017-09-11 | 2023-10-03 | 阿托萨治疗学公司 | Methods of making and using endoxifen |
JP7244495B2 (en) | 2017-09-13 | 2023-03-22 | リビング プルーフ インコーポレイテッド | Long lasting cosmetic composition |
CN111065665B (en) | 2017-09-13 | 2023-03-17 | 生活实验公司 | Color protectant compositions |
CN112805044A (en) * | 2018-08-23 | 2021-05-14 | 尼普洛株式会社 | Extracellular fluid volume calculation device and extracellular fluid volume calculation method |
CN111150888B (en) * | 2018-11-07 | 2022-03-15 | 财团法人工业技术研究院 | Double-effect film and preparation method thereof |
CN109821076B (en) * | 2019-03-13 | 2021-05-07 | 陕西师范大学 | Preparation method of multifunctional anticoagulant and anti-infection coating and multifunctional anticoagulant and anti-infection material |
CN109820748B (en) * | 2019-03-25 | 2021-10-22 | 昆明蓝橙口腔医院有限责任公司 | Moisture-free matrix for oral products and application thereof |
CN111848832B (en) * | 2019-04-30 | 2024-02-20 | 苏州大学 | Application of fluorine-containing compound modified cationic polymer as drug carrier and preparation method thereof |
US20220016025A1 (en) * | 2020-07-08 | 2022-01-20 | Vinayak Dinesh DENDUKURI | Formulations of nebivolol |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US33273A (en) * | 1861-09-10 | Improvement in railroad-car wheels | ||
US147238A (en) * | 1874-02-10 | Improve went in loom-harness | ||
US119188A (en) * | 1871-09-19 | Improvement in processes and apparatus for extracting fatty substances | ||
US48596A (en) * | 1865-07-04 | Improved washing-machine | ||
US12680A (en) * | 1855-04-10 | Railroad-cab | ||
US12849A (en) * | 1855-05-15 | Adams | ||
US106345A (en) * | 1870-08-16 | Improvement in recording pressure-gages | ||
US3179A (en) * | 1843-07-20 | Machine for sawing clapboards | ||
US37877A (en) * | 1863-03-10 | Improvement in lining lead pipes with tin | ||
US4369182A (en) | 1978-09-27 | 1983-01-18 | A. Nattermann & Cie Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
JPS55153713A (en) | 1979-05-02 | 1980-11-29 | Kureha Chem Ind Co Ltd | Pharmaceutical preparation of ribosome containing active substance |
IL64397A0 (en) | 1981-01-07 | 1982-02-28 | Weder Hans G | Process for the preparation of liposomal medicaments |
EP0088046B1 (en) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipids in the aqueous phase |
EP0102324A3 (en) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
USRE33273E (en) * | 1982-08-18 | 1990-07-24 | Georgia Tech Research Corporation | Materials having improved nonfouling characteristics and method of making same |
FR2542998B1 (en) | 1983-03-24 | 1986-01-31 | Rhone Poulenc Sante | NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE |
GB8321913D0 (en) | 1983-08-15 | 1983-09-14 | Acacia Chem Ltd | Spray method |
EP0152379A3 (en) | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Process for preparing pharmaceutical compositions containing unilamellar liposomes |
US4897269A (en) | 1984-09-24 | 1990-01-30 | Mezei Associates Limited | Administration of drugs with multiphase liposomal delivery system |
US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
IN166447B (en) | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
DE3542773A1 (en) | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | SKIN-ACTIVE PHARMACA WITH LIPOSOMES AS AN ACTIVE SUBSTANCE |
US4937182A (en) | 1985-12-19 | 1990-06-26 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
US5244678A (en) | 1986-01-14 | 1993-09-14 | Ire-Celltarg S.A. | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes |
FR2597367B1 (en) | 1986-04-22 | 1988-07-15 | Oreal | PROCESS FOR FACILITATING THE FORMATION OF LIPID SPHERULES DISPERSION IN AN AQUEOUS PHASE AND FOR IMPROVING THEIR STABILITY AND THEIR ENCAPSULATION RATE, AND CORRESPONDING DISPERSIONS. |
US5154930A (en) | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4855090A (en) | 1987-03-13 | 1989-08-08 | Micro-Pak, Inc. | Method of producing high aqueous volume multilamellar vesicles |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US5238613A (en) * | 1987-05-20 | 1993-08-24 | Anderson David M | Microporous materials |
US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4983395A (en) | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4937078A (en) | 1988-08-26 | 1990-06-26 | Mezei Associates Limited | Liposomal local anesthetic and analgesic products |
US5043165A (en) | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
ATE104862T1 (en) | 1989-08-03 | 1994-05-15 | Hisamitsu Pharmaceutical Co | SKIN CREAM PREPARATION FOR EXTERNAL USE. |
US5104661A (en) | 1989-08-14 | 1992-04-14 | Technology Unlimited, Inc. | Reverse loading of liposomes |
US5209720A (en) | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
DE4107153A1 (en) | 1991-03-06 | 1992-09-10 | Gregor Cevc | Compsns. for application of active agents |
CA2067754C (en) | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
DE4107152C2 (en) | 1991-03-06 | 1994-03-24 | Gregor Cevc | Preparations for non-invasive administration of antidiabetics |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
US5202125A (en) | 1990-12-10 | 1993-04-13 | Theratech, Inc. | Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
JP2922017B2 (en) | 1991-03-25 | 1999-07-19 | 第一製薬株式会社 | Oral lipid membrane structure |
US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
HU223343B1 (en) | 1991-05-20 | 2004-06-28 | Novartis Ag. | Compositions comprising allylamine derivatives, and process for their preparation |
JP2579729B2 (en) | 1991-06-10 | 1997-02-12 | シュバルツ ファルマ アクチェンゲゼルシャフト | Nitroglycerin plaster and method for producing the same |
GB9116610D0 (en) | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
WO1993007902A1 (en) | 1991-10-16 | 1993-04-29 | Richardson-Vicks, Inc. | Enhanced skin penetration system for improved topical delivery of drugs |
EG20380A (en) | 1991-10-16 | 1999-02-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
US5985860A (en) | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
ATE152630T1 (en) | 1992-07-28 | 1997-05-15 | Procter & Gamble | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSS-LINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER |
DK0616799T3 (en) | 1993-03-24 | 2000-09-18 | Collaborative Lab Inc | Cosmetic application system for salicylic acid and process for their preparation |
DE4336557C2 (en) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiol-containing transdermal therapeutic system, process for its preparation and its use |
US5460820B1 (en) | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
FR2714601B1 (en) | 1993-12-30 | 1996-02-09 | Oreal | Depigmenting composition for the simultaneous treatment of surface and deep layers, its use. |
US5536263A (en) * | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
CA2201358C (en) | 1994-09-30 | 2004-06-08 | Jurgen Regenold | Pharmaceutical composition |
IT1270678B (en) | 1994-10-20 | 1997-05-07 | Bayer Ag | KETOPROFEN LIPOSOMES |
US20020048596A1 (en) | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
DE4447287C1 (en) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Droplet-in-fluid composition to transport agent e.g. through skin |
US5763422A (en) | 1995-01-27 | 1998-06-09 | Board Of Regents, The University Of Texas System | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
IT1275955B1 (en) | 1995-03-22 | 1997-10-24 | Dompe Spa | PHARMACEUTICAL FORMULATIONS IN THE FORM OF THISSOTROPIC GEL |
US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
DE19512181C2 (en) | 1995-03-31 | 2003-11-06 | Hexal Pharma Gmbh | Transdermal system with ramipril and / or trandolapril as an ACE inhibitor |
DE19518221A1 (en) | 1995-05-10 | 1996-11-14 | Schering Ag | Use of non-steroidal anti-inflammatories to improve the physiological tolerance of particulate pharmaceutical preparations |
US6214386B1 (en) | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US5891472A (en) | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
WO1998030215A1 (en) * | 1997-01-13 | 1998-07-16 | Cilag Ag | Liposome-based topical tretinoin formulation |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
DE69837664T2 (en) | 1997-05-14 | 2008-01-03 | Senju Pharmaceutical Co., Ltd. | AQUEOUS SUSPENSION PREPARATIONS WITH EXCELLENT REDISPERSIBILITY |
US6083996A (en) | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
IT1298214B1 (en) | 1998-01-28 | 1999-12-20 | Dompe Spa | SALTS OF (R) 2- (3-BENZOYLFENYL) PROPIONIC ACID AND THEIR PHARMACEUTICAL COMPOSITIONS. |
US6193996B1 (en) | 1998-04-02 | 2001-02-27 | 3M Innovative Properties Company | Device for the transdermal delivery of diclofenac |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
SE9802864D0 (en) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as an antimuscarinic agent for the treatment of overactive bladder |
AU6026099A (en) | 1998-09-03 | 2000-03-27 | Loma Linda University Medical Center | Pharmaceutical composition and method for treatment of inflammation |
JP2002533379A (en) * | 1998-12-23 | 2002-10-08 | イデア アクチェンゲゼルシャフト | Improved formulation for locally non-invasive use in vivo |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6362227B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor, Inc. | Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen |
US7063859B1 (en) * | 1999-04-28 | 2006-06-20 | Noven Pharmaceuticals, Inc. | Barrier film lined backing layer composition and method for topical administration of active agents |
WO2000078407A1 (en) | 1999-06-18 | 2000-12-28 | Powerlung Inc | Pulmonary exercise device |
MXPA02000053A (en) * | 1999-07-05 | 2003-07-21 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers. |
JP2001036949A (en) * | 1999-07-19 | 2001-02-09 | Hitachi Ltd | Method and system for radio communication |
US6685928B2 (en) | 1999-12-07 | 2004-02-03 | Rutgers, The State University Of New Jersey | Therapeutic compositions and methods |
US6248353B1 (en) | 1999-12-10 | 2001-06-19 | Dade Behring Inc. | Reconstitution of purified membrane proteins into preformed liposomes |
US6835394B1 (en) * | 1999-12-14 | 2004-12-28 | The Trustees Of The University Of Pennsylvania | Polymersomes and related encapsulating membranes |
US6562370B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
US6586000B2 (en) | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6645520B2 (en) | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
US6582724B2 (en) | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
EP1116485A3 (en) | 2000-01-10 | 2002-01-16 | Gerhard Dr. Gergely | Instant granulate and process for its preparation |
US20020119188A1 (en) | 2000-02-08 | 2002-08-29 | Susan Niemiec | Method of manufacturing liposomes |
ES2303527T3 (en) | 2000-05-10 | 2008-08-16 | Jagotec Ag | GRINDING PROCEDURE. |
AU2001277891A1 (en) | 2000-07-26 | 2002-02-05 | Alcon Universal Ltd. | Pharmaceutical suspension compositions lacking a polymeric suspending agent |
US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
JP2002063747A (en) * | 2000-08-18 | 2002-02-28 | Sony Corp | Recording medium, recording medium master plate, and method for manufacturing recording medium |
KR20030079784A (en) * | 2002-04-04 | 2003-10-10 | 마츠시타 덴끼 산교 가부시키가이샤 | Refrigerating cycle apparatus |
US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
US7387788B1 (en) * | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
-
1999
- 1999-07-05 MX MXPA02000053A patent/MXPA02000053A/en not_active Application Discontinuation
- 1999-07-05 AU AU54096/99A patent/AU5409699A/en not_active Withdrawn
- 1999-07-05 WO PCT/EP1999/004659 patent/WO2001001962A1/en active Application Filing
-
2000
- 2000-07-05 CN CN00809916A patent/CN1359288A/en active Pending
- 2000-07-05 EE EEP200200008A patent/EE200200008A/en unknown
- 2000-07-05 AU AU61557/00A patent/AU779765B2/en not_active Ceased
- 2000-07-05 PL PL00352380A patent/PL352380A1/en not_active Application Discontinuation
- 2000-07-05 JP JP2001507458A patent/JP2003503442A/en not_active Ceased
- 2000-07-05 KR KR1020017016947A patent/KR100852901B1/en not_active IP Right Cessation
- 2000-07-05 EP EP00947939A patent/EP1189598A1/en not_active Ceased
- 2000-07-05 HU HU0201454A patent/HUP0201454A3/en unknown
- 2000-07-05 BR BR0012178-9A patent/BR0012178A/en not_active Application Discontinuation
- 2000-07-05 CA CA002375157A patent/CA2375157A1/en not_active Abandoned
- 2000-07-05 WO PCT/EP2000/006367 patent/WO2001001963A1/en active Application Filing
- 2000-07-05 RU RU2002101651/15A patent/RU2260445C2/en not_active IP Right Cessation
- 2000-07-05 CZ CZ200238A patent/CZ200238A3/en unknown
-
2001
- 2001-11-27 HR HR20010881A patent/HRP20010881A2/en not_active Application Discontinuation
-
2002
- 2002-01-04 NO NO20020032A patent/NO20020032L/en not_active Application Discontinuation
- 2002-01-04 US US10/037,480 patent/US7459171B2/en not_active Expired - Fee Related
- 2002-08-30 HK HK02106448.3A patent/HK1046356A1/en unknown
-
2004
- 2004-11-08 US US10/984,450 patent/US7591949B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2572959C2 (en) * | 2010-06-29 | 2016-01-20 | Кордис Корпорейшн | Method for medicinal product packing into implantable medical devices (versions) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002101651A (en) | Method for improving transportation through an easily adjustable semipermeable barrier | |
RU2207844C2 (en) | Improved preparation for topical non-invasive using in vivo | |
RU2260445C2 (en) | Method for improving transportation through easily adaptable semi-permeable barrier | |
JP2003503442A5 (en) | ||
RU2001120008A (en) | Advanced in vivo topical, non-invasive topical preparation | |
US11679157B2 (en) | Controlled release mucoadhesive systems | |
ES2916803T3 (en) | Vesicular formulations for use in the treatment of pain or reduced mobility of a joint | |
ES2845524T3 (en) | Non-aqueous patch | |
JP2021091730A (en) | Multiphasic compositions | |
KR101452536B1 (en) | Transdermal therapeutic system for administering water-soluble active ingredients | |
WO2016156470A1 (en) | Vesicular formulations for use in the treatment of muscle soreness | |
KR20060088906A (en) | Improved formulation for topical non-invasive application in vivo |